Method: A retrospective, comparative study was designed to assess the outcome of intravitreal anti-VEGF therapy on IOP. The medical charts of patients treated with intravitreal anti-VEGF (bevacizumab-ranibizumab-aflibercept) for age-related macular degeneration (AMD) from January 2012 to March 2017 were retrospectively reviewed. Patients with any other history of primary open angle glaucoma, pseudoexfoliation syndrome, steroid therapy, intraocular surgery except cataract surgery and patients with the complications such as endophthalmitis, traumatic cataract after intravitreal anti-VEGF injection and with a follow-up shorter than 6 months were excluded. Two groups were defi ned for the primary endpoint of this study. Patients with IOP elevation ?6 mmHg and final IOP <21 mmHg were defi ned as group 1 and patients with IOP elevation ?6 mmHg and final IOP >21 mmHg were defi ned as group 2.

Results: 7.2% of all patients had a signifi cant IOP elevation. Patients included in group 1 was signifi cantly higher in the bevacizumab group than in the ranibizumab and afl ibercept groups (p=0.041 and p=0.038, respectively). The number of patients included in group 2 although not statistically signifi cant was higher in the bevacizumab group than in the ranibizumab and afl ibercept groups (p=0.21 and p=0.13, respectively). In regression analysis, a positive relationship between mean injection number and IOP elevation was shown in bevacizumab group. (p:0.001- adjusted R square 0.63)

Conclusion: The results of this study show that bevacizumab therapy can cause a signifi cant IOP elevation, and its effect on the IOP was stronger than that of afl ibercept and ranibizumab. The clinicians should try to keep the number of injections to a minimum, especially for patients with glaucoma histories. We also suggest that ranibizumab and afl ibercept might be a clinician?s first choices, especially in a patient with a history of glaucoma. Keywords : Göz içi basınç, anti-vasküler endotelyal büyüme faktörü,bevacizumab, ranibizumab, aflibercept